Despite a pointed decision by the Federal Circuit vacating and remanding the matter to the Patent Trial and Appeal Board, yesterday the Board once again granted priority for CRISPR technology to the Broad Institute. A more detailed discussion of the basis for this judgment will follow.
Patent Law Weblog
recent posts
- Amici Address Section 1498 Scope in Moderna COVID-19 Infringement Appeal: In Favor of Affirmance
- Arbutus Responds to Moderna’s Appeal of District Court Infringement Judgment over COVID Vaccines
- Moderna Appeals District Court Infringement Judgment over COVID Vaccines
- USPTO Requires Foreign-domiciled Patent Applicants and Owners to Be Represented by USPTO-registered Practitioners
- Extremity Medical, LLC v. Nextremity Solutions, Inc. (Fed. Cir. 2026)
Patent Docs 
Leave a comment